Cubist Makes Attractive Takeover Bid for Adolor (ADLR, $1.91)Monday, October 24, 2011 · 9:07 am |
|
Check with Adolor Management on Entereg Marketing Transition and Progress of Partnering Discussions on ADL 5945 (ADLR, $2.05)Thursday, September 15, 2011 · 1:17 pm |
|
Phase II Data for ADL 5945 in Opiod Induced Constipation is Excellent (ADLR, $2.23)Wednesday, August 10, 2011 · 9:16 am |
|
Prospects for Entereg May Justify $4.50 Price Target for 2013 (ADLR, $2.20)Wednesday, August 10, 2011 · 7:10 am |
|
Upgrading to Buy Based On Regaining Glaxo's Rights in Entereg (ADLR, $1.65)Thursday, June 16, 2011 · 12:30 pm |
|
Analysis of Adolor's 1Q, 2011 and A Look Forward (ADLR, $1.39)Wednesday, April 27, 2011 · 7:00 pm |
|
Initial Report on Adolor (ADLR, $1.38)Thursday, February 10, 2011 · 7:00 pm |
|
|
There are 7 reports on file. |
